Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
ANK-101 by Ankyra Therapeutics for Solid Tumor: Likelihood of Approval
ANK-101 is under clinical development by Ankyra Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Data Insights
ANK-101 by Ankyra Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
ANK-101 is under clinical development by Ankyra Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...